Plazzer et al., MMR specific ACMG-AMP criteria

# 1 Mismatch repair gene specifications to the ACMG/AMP

- 2 classification criteria: Consensus recommendations from
- <sup>3</sup> the InSiGHT ClinGen Hereditary Colorectal Cancer /

## 4 Polyposis Variant Curation Expert Panel

- 5 John Paul Plazzer<sup>1</sup>, Finlay Macrae<sup>1,2</sup>, Xiaoyu Yin<sup>2</sup>, Bryony A. Thompson<sup>3</sup>, Susan M Farrington<sup>4</sup>, Lauren Currie<sup>5</sup>,
- 6 Kristina Lagerstedt-Robinson<sup>6</sup>, Jane Hübertz Frederiksen<sup>7</sup>, Thomas van Overeem Hansen<sup>7,8</sup>, Lise Graversen<sup>9</sup>, Ian M.

7 Frayling<sup>10</sup>, Kiwamu Akagi<sup>11</sup>, Gou Yamamoto<sup>11</sup>, Fahd Al-Mulla<sup>12</sup>, Matthew J. Ferber<sup>13</sup>, Alexandra Martins<sup>14</sup>, Maurizio

- 8 Genuardi<sup>15,16</sup>, Maija Kohonen-Corish<sup>17</sup>, Stéphanie Baert-Desurmont<sup>18</sup>, Amanda B. Spurdle<sup>19</sup>, Gabriel Capellá<sup>20,21</sup>,
- 9 Marta Pineda<sup>20,21</sup>, Michael O. Woods<sup>22</sup>, Lene Juel Rasmussen<sup>23,24</sup>, Christopher D. Heinen<sup>25</sup>, Rodney J. Scott<sup>26,27</sup>, Carli
- 10 M. Tops<sup>28</sup>, Marc S. Greenblatt<sup>29</sup>, Mev Dominguez-Valentin<sup>30</sup>, Elisabet Ognedal<sup>31</sup>, Ester Borras<sup>32</sup>, Suet Y. Leung<sup>33</sup>,
- 11 Khalid Mahmood<sup>34,35,36</sup>, Elke Holinski-Feder<sup>37,38</sup>, Andreas Laner<sup>37</sup>
- 12
- 13 <sup>1</sup>Department of Colorectal Medicine and Genetics, Royal Melbourne Hospital, Parkville, Australia
- 14 <sup>2</sup> Department of Medicine, University of Melbourne, Royal Melbourne Hospital, Parkville Australia
- 15 <sup>3</sup> Department of Pathology, Royal Melbourne Hospital, Parkville, Australia
- 16 <sup>4</sup>Colorectal Cancer Genetics Group, CRUK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Scotland
- 17 <sup>5</sup>GeneDx LLC, Gaithersburg, MD, USA
- 18 <sup>6</sup> Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden
- 19 <sup>7</sup> Department of Clinical Genetics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
- 20 <sup>8</sup> Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
- 21 <sup>9</sup> Department of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark
- 22 <sup>10</sup> Inherited Tumour Syndromes Research Group, Institute of Medical Genetics, Cardiff University, CF14 4XN, UK
- 23 <sup>11</sup> Department of Molecular Diagnosis and Cancer Prevention, Saitama Cancer Center, Saitama, Japan
- 24 <sup>12</sup> Department of Genetics and Bioinformatics, Dasman Diabetes Institute, Kuwait
- 25 <sup>13</sup> Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA
- 26 <sup>14</sup> Univ Rouen Normandie, Inserm U1245, F-76000 Rouen, France
- 27 <sup>15</sup> Dipartimento di Scienze della Vita e Sanità Pubblica, Università Cattolica del Sacro Cuore, Rome, Italy
- 28 <sup>16</sup> UOC Genetica Medica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
- 29 <sup>17</sup> Woolcock Institute of Medical Research, Macquarie University, Sydney, Australia
- 30 <sup>18</sup> Univ Rouen Normandie, Inserm U1245 and CHU Rouen, Department of Genetics, F-76000 Rouen, France
- 31 <sup>19</sup> Population Health Program, QIMR Berghofer Medical Research Institute, Herston, Australia
- 32 <sup>20</sup> Hereditary Cancer Program, Catalan Institute of Oncology, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), ONCOBELL Program,
- 33 L'Hospitalet de Llobregat, Barcelona, Spain
- 34 <sup>21</sup> Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain
- 35 <sup>22</sup> Discipline of Genetics, Memorial University of Newfoundland, St John's, NL, Canada
- 36 <sup>23</sup> Center for Healthy Aging, University of Copenhagen, Copenhagen, DK-2200 Copenhagen, Denmark

Plazzer et al., MMR specific ACMG-AMP criteria

- 37 <sup>24</sup> Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, DK-2200 Copenhagen, Denmark
- 38 <sup>25</sup> Center for Molecular Oncology, UConn Health, Farmington, CT, USA
- 39 <sup>26</sup> Division of Molecular Medicine, NSW Health Pathology North – Newcastle, NSW 2305, Australia
- 40 <sup>27</sup> The Hunter Medical Research Institute and the University of Newcastle, Newcastle, NSW, Australia
- 41 <sup>28</sup> Department of Clinical Genetics, Leiden University Medical Center, The Netherlands
- 42 43 <sup>29</sup> Department of Medicine, University of Vermont Cancer Center, Larner College of Medicine, Burlington VT, USA
- <sup>30</sup> Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
- 44 <sup>31</sup> Western Norway Familial Cancer Center, Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway
- 45 <sup>32</sup> Invitae Corporation, San Francisco, California, USA
- 46 <sup>33</sup> Department of Pathology, School of Clinical Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong SAR, China
- 47 <sup>34</sup> Colorectal Oncogenomics Group, Department of Clinical Pathology, Victorian Comprehensive Cancer Centre, The University of Melbourne,
- 48 Parkville, Victoria, 3010, Australia
- 49 <sup>35</sup> University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville, Victoria 3010 Australia
- 50 <sup>36</sup> Melbourne Bioinformatics, The University of Melbourne, Melbourne, Victoria, Australia
- 51 <sup>37</sup> MGZ – Medizinisch Genetisches Zentrum, Bayerstr. 3-5, 80035 Munich, Germany
- 52 <sup>38</sup> Medizinische Klinik und Poliklinik IV, Campus Innenstadt, Klinikum Der Universität München, 80336 Munich, Germany
- 53
- 54 On behalf of the InSiGHT - ClinGen Hereditary Colon Cancer / Polyposis Variant Curation Expert Panel 55

#### List of abbreviations: 56

- 57 ACMG – American College of Medical Genetics and Genomics •
- 58 AMP – Association for Molecular Pathology •
- 59 B – Benign •
- 60 BA – Benign Stand-Alone •
- 61 • BS – Benign Strong
- 62 • **BP** – Benign Supporting
- 63 ClinGen – Clinical Genome Resource •
- 64 • CMMRD – constitutional mismatch repair deficiency
- 65 GI – gastrointestinal •
- 66 • gnomAD – Genome Aggregation Database
- 67 FDA – Food and Drug Administration (United States) •
- 68 • HCI – Huntsman Cancer Institute
- 69 HGVS – Human Genome Variation Society •
- 70 • IARC – International Agency for Research on Cancer
- 71 IHC – immunohistochemistry ٠

Plazzer et al., MMR specific ACMG-AMP criteria

- InSiGHT International Society for Gastrointestinal Hereditary Tumours
- IVS intervening sequence (intron)
- LB likely benign
- 75 LP likely pathogenic
- 76 LOVD Leiden Open Variation Database
- LS Lynch syndrome
- MANE matched annotation from National Center for Biotechnology Information and European
- 79 Molecular Biology Laboratory and European Bioinformatics Institute
- MMR mismatch repair (genes)
- MSI microsatellite instability
- NGS next generation sequencing
- 83 NMD nonsense–mediated mRNA decay
- 84 P Pathogenic
- PVS Pathogenic Very Strong
- 86 PS Pathogenic Strong
- 87 PM Pathogenic Moderate
- 88 PP Pathogenic Supporting
- SVI WG Sequence Variant Interpretation Working Group
- 90 VCEP variant curation expert panel
- 91 VUS variant of uncertain significance

Plazzer et al., MMR specific ACMG-AMP criteria

## 92 Abstract

Background: It is known that gene- and disease-specific evidence domains can potentially improve the
 capability of the ACMG/AMP classification criteria to categorize pathogenicity for variants. We aimed to
 include gene-disease-specific clinical, predictive, and functional domain specifications to the
 ACMG/AMP criteria with respect to MMR genes.

97 **Methods:** Starting with the original criteria (InSiGHT criteria) developed by the InSiGHT Variant 98 Interpretation Committee, we systematically addressed specifications to the ACMG/AMP criteria to 99 enable more comprehensive pathogenicity assessment within the ClinGen VCEP framework, resulting in 100 an MMR gene-specific ACMG/AMP criteria.

101 **Results:** A total of 19 criteria were specified, 9 were considered not applicable and there were 35 102 variations of strength of the evidence. A pilot set of 48 variants was tested using the new MMR gene-103 specific ACMG/AMP criteria. Most variants remained unaltered, as compared to the previous InSiGHT 104 criteria; however, an additional four variants of uncertain significance were reclassified to P/LP or LB by 105 the MMR gene-specific ACMG/AMP criteria framework.

106 Conclusion: The MMR gene-specific ACMG/AMP criteria have proven feasible for implementation, are 107 consistent with the original InSiGHT criteria, and enable additional combinations of evidence for variant 108 classification. This study provides a strong foundation for implementing gene–disease-specific 109 knowledge and experience, and could also hold immense potential in a clinical setting.

Plazzer et al., MMR specific ACMG-AMP criteria

# 121 **1 Introduction**

122 Lynch syndrome, previously referred to as hereditary nonpolyposis colorectal cancer, is caused by a 123 heterozygous constitutional pathogenic loss of function of a mismatch repair (MMR) gene, which is 124 either MLH1 (OMIM 120436), MSH2 (OMIM 609309), MSH6 (OMIM 600678), or PMS2 (OMIM 600259). 125 It can also arise from the deletion of the 3'end of EPCAM (TACSTD1), which results in hypermethylation 126 of the MSH2 promoter. These factors foster the accumulation of somatic mutations that cannot be 127 corrected by the defective machinery, resulting in tumors with a microsatellite instability (MSI)-high 128 phenotype. Although the tumor spectrum is variegated, colorectal or endometrial cancers predominate. 129 Strategies aimed at identifying carriers of pathogenic variants range from ascertainment of family 130 history, testing for MMR-deficient cancers in patients, to universal constitutional sequencing of patients 131 presenting with colorectal (Tiwari, 2016) or endometrial cancers (Kahn, 2019).

132

133 A public database of germline MMR variants and variants involved in other familial gastrointestinal (GI) 134 cancer syndromes has long been maintained by the International Society for Gastrointestinal Hereditary 135 Tumors (InSiGHT), the preeminent professional body representing healthcare workers, researchers, and 136 medical geneticists interested in familial GI cancer. The InSiGHT databases for inherited GI cancer 137 syndromes centralize data and aid expert variant classification (Plazzer, 2013). Since the 1990s, MMR 138 variants have steadily accrued, with changes in technology accompanying significant increases in the 139 identified variants. By 2023, the number of unique constitutional MMR variants in public variant 140 databases reached over 6,500 in LOVD and over 23,000 in ClinVar. In 2014, the InSiGHT Variant 141 Interpretation Committee criteria for the classification of MMR variants were published (Thompson, 142 2014), and the committee was thereafter recognized as an external expert panel by ClinGen (Rehm, 143 2015). The landmark American College of Medical Genetics and Genomics/Association for Molecular 144 Pathology (ACMG/AMP) variant classification criteria were published in 2015 (Richards, 2015), proposing 145 generic classification criteria requiring gene or disease specifications. They were soon adopted by many 146 gene-disease expert groups, including those within the Variant Curation Expert Panel (VCEP) framework 147 developed by ClinGen (Rivera-Muñoz, 2018). Latterly these have been recognized by the Food and Drug 148 Administration (FDA) as a regulated source for curating variants.

149

Following an agreement between InSiGHT and ClinGen, the Hereditary Colorectal Cancer/Polyposis VCEP
(https://clinicalgenome.org/affiliation/50099/) was formed out of the existing InSiGHT Variant

Plazzer et al., MMR specific ACMG-AMP criteria

152 Interpretation Committee, and was expanded to other genes predisposing hereditary GI cancer, 153 including *APC*, *MUTYH*, *STK11*, *POLD1*, *POLE*, *SMAD4*, and *BMPR1A*, for which there is substantial 154 expertise within the membership of InSiGHT. As this VCEP covers multiple genes for several hereditary 155 GI tumors, it has been divided into sub-VCEP groups for organizational efficiency. Here, we describe the 156 work of the MMR VCEP subgroup in adapting gene-specific ACMG/AMP criteria and the validation of the 157 criteria through pilot variant classification.

# 158 2 Methods

#### 159 2.1 InSiGHT-ClinGen MMR VCEP

We made an application to be recognized as a ClinGen internal VCEP to ClinGen, which was approved by ClinGen in February 2021. This involved listing of the group's members, expertise, and scope of our curation activity. Members of the InSiGHT ClinGen Hereditary Colorectal Cancer/Polyposis Variant Curation Expert Panel (<u>https://clinicalgenome.org/affiliation/50099/</u>) have diverse technical and clinical expertise from the private, public, research, and healthcare sectors. There is a broad international representation of GI surgeons, genetic counsellors, medical geneticists, oncologists, scientists, bioinformaticians, and clinical laboratory diagnosticians.

## 167 2.2 Gene–disease specifications to the ACMG/AMP criteria

168 Previously, the InSiGHT criteria (https://www.insight-group.org/criteria/) used predetermined 169 combinations of evidence and a Bayesian analysis component, which incorporated in silico prediction, 170 tumor characteristics, functional assay, and variant-disease segregation (Thompson, 2013). These 171 criteria inform the new ACMG/AMP specifications for MMR genes. The ACMG/AMP framework uses 172 weight of evidence corresponding to Supporting, Moderate, Strong, and Very Strong categories (Figure 173 1). Furthermore, these categories are calibrated against likelihood ratio (LR) thresholds from modelling 174 that align the ACMG/AMP criteria with a Bayesian probability framework (Tavtigian, 2018). Therefore, 175 while both current and original InSiGHT criteria utilize Bayesian methods, the new criteria integrate the 176 evidence combinations and Bayesian probabilities into a single framework. Our ACMG/AMP 177 specifications are updated periodically; to find the latest information, please visit: 178 https://cspec.genome.network.

Plazzer et al., MMR specific ACMG-AMP criteria

### 180 2.3 LS penetrance

181 The ACMG/AMP criteria can classify high-penetrance MMR variants for LS, while comparatively low- or 182 moderate-risk variants cannot be classified owing to scarcity of data (Dominguez-Valentin, 2021). PMS2 183 variants are an exception, as this gene is recognized for having low-penetrance; therefore, loss of 184 function variants are presumed to confer a low risk of cancer in carriers of heterozygous PMS2 185 pathogenic variants. Information on risks of cancer according to organ, age, gender, and gene 186 (Dominguez-Valentin, 2020) is available on the Prospective Lynch Syndrome Database (PLSD: 187 www.PLSD.eu). Estimates of the penetrance of LS also inform segregation analysis by accounting for LS-188 specific cancer risk, dependent on the age of the patient at diagnosis and their sex. This VCEP 189 recommends the COsegregation OnLine v3 tool (Belman, 2020), which incorporates penetrance for 190 MMR genes and has a free public web interface (https://fengbj-laboratory.org/cool2/manual.html).

191

### 192 2.4 Inclusion of tumor characteristics

193 One of the hallmarks of LS, observed in respective tumors, is the microsatellite instability (MSI) and 194 MMR immunohistochemistry (IHC) pattern demonstrating a loss of protein expression. Loss of MMR 195 protein expression is highly concordant (98%) with the MSI status in LS, though MSI more commonly 196 occurs outside the context of LS in sporadic colorectal or endometrial cancer (Latham, 2019). It is also 197 recognized that individuals with LS can still develop sporadic microsatellite stable (MSS) cancers, which 198 is not due to their constitutional variant. In a study (Li, 2020) on MSI/IHC status and the application of 199 variant classification, the researchers achieved 98% accuracy in variant classification when combined 200 with in silico, clinical/family history, co-segregation, allele frequency, and co-occurrence data. The 201 ACMG/AMP criteria incorporates these data types and the updated tumor characteristic likelihood 202 ratios from the study by Li et al. MSI/MSS and IHC data are specified in the criteria for colorectal and 203 endometrial cancers owing to existing calibration studies of these particular tumor characteristics with 204 germline pathogenic variants. Reciprocally, tumor IHC is also specified for any LS spectrum tumor having 205 protein expression that is inconsistent with the gene demonstrating the variant.

Plazzer et al., MMR specific ACMG-AMP criteria

## 207 2.5 Functional assay specifications

208 New recommendations for the application of the functional evidence types PS3/BS3 (Brnich, 2020) 209 assign the strength of the ACMG/AMP evidence, depending on the level of statistical analysis used for 210 assay validation. As per the Brnich et al. recommendation, at least 11 controls are required to reach a 211 Moderate level evidence and a rigorous statistical analysis to reach a Strong level of evidence. There are 212 currently three assays recognized with calibrated odds of pathogenicity that reach a Strong level of 213 evidence (PS3), namely, the Complete in vitro MMR Assay (CIMRA) for MLH1, MSH2, MSH6, and PMS2 214 (Drost, 2019), (Drost, 2020), (Rayner, 2022), a deep mutational scan of MSH2 (Scott, 2022) (Jia, 2021), 215 and a cell-based assay for MLH1 (Rath A, 2022). These assays employed rigorous statistical analysis 216 calibrating the level of *in vitro* MMR activity to the corresponding probability of pathogenicity. They 217 have, therefore, been validated to reach Supporting, Moderate, or Strong level of evidence for PS3 and 218 Supporting or Strong for BS3 evidence (Supplementary Table 1).

219

220 In addition to the calibrated functional assays, a decision tree (Figure 2) logically combines other types 221 of functional assay to test different aspects of MMR function, such as protein expression, subcellular 222 localization, and RNA splicing, to determine if a variant leads to proficient or deficient function. It was 223 published in 2014 (Thompson, 2014) and updated in 2020 (Thompson, 2020), and is now incorporated 224 into the VCEP MMR criteria, though calibrated assays are recommended for prospective variant analysis. 225 For the assays detailed in the functional assay decision tree, as per Brnich et al, the criterion of a 226 minimum number of 11 pathogenic and benign controls has been met for each type of assay 227 (Supplementary Table 1); this excludes splicing assays, which have specific requirements in the criteria 228 descriptions. The decision tree is used for interpreting previous or historical assay results, not as a guide 229 for performing prospective assays of which we recommend the calibrated assays.

230

## 231 2.6 In silico variant effect predictions tools

In silico meta-predictor tools and tools calibrated for all missense variants in specific genes offer improved performance, as compared to individual predictors (Tian, 2019) (Pejaver, 2022). Here, the PP3/BP4 criteria for *in silico* evidence were derived from previous analyses described in (Thompson, 2013). Briefly, Thompson et.al. (2013) calibrated individual *in silico* variant effect prediction tools against MMR variants with designated pathogenicity, showing that a combination of MAPP-MMR and Polyphen-

Plazzer et al., MMR specific ACMG-AMP criteria

2 predictors showed higher performance, in terms of specificity and sensitivity, as compared to other individual tools. For MLH1, MSH2, and MSH6 missense variants, pre-computed prior probabilities are available online (<u>https://hci-priors.hci.utah.edu/PRIORS/</u>) that map to Supporting, Moderate, or Strong evidence. Similarly, for PMS2 missense variants, we recommend using the HCI "MAPP/PP2 Prior P" predictions available at <u>http://hci-lovd.hci.utah.edu/variants.php?select\_db=PMS2\_priors</u>. For intronic and synonymous variants, we recommend predicting splice altering consequence with SpliceAI (Riepe, 2021).

## 244 2.7 Pilot variant classification

245 A series of teleconferences between 2020 and 2021 were held to merge the existing InSiGHT MMR-246 specific criteria with the ACMG/AMP criteria in a ClinGen VCEP framework. Feedback from the ClinGen Sequence Variant Interpretation Working Group (SVI WG) was incorporated into the criteria, and the SVI 247 248 WG approved the criteria in May 2022. Following the creation of the initial draft of the criteria, a pilot 249 batch of 48 variants were manually selected from the InSiGHT and ClinVar databases to assess whether 250 their classification could be changed from variant of uncertain significance (VUS), likely benign (LB), or 251 likely pathogenic (LP), using the new criteria and/or new information. The variants were curated for this 252 study using existing information from public databases and literature, the Colon Cancer Family Registry 253 (www.coloncfr.org), as well as information from VCEP members which are available on LOVD. The types 254 of variants included intronic, splice site, missense, synonymous, in-frame deletion, nonsense, and 255 frameshift variants. Variants were reviewed independently by experts and biocurators, followed by 256 VCEP teleconference discussions. Disparities between reviewers were discussed and appropriate 257 revisions to the criteria were made. Biocurators entered the variants, the ACMG/AMP criteria that was 258 met, summary text and classifications into the ClinGen Variant Curation Interface tool (Preston, 2022) to 259 obtain a 3-star VCEP classification status within the FDA-recognized ClinGen framework.

## 260 2.8 Selection of transcripts

The preferred MANE Select transcripts are NM\_000249.4 (*MLH1*), NM\_000251.3 (*MSH2*), NM\_000179.3
(*MSH6*), and NM\_000535.7 (*PMS2*). Variants are described using the Human Genome Variation Society
(HGVS) nomenclature (https://varnomen.hgvs.org/).

Plazzer et al., MMR specific ACMG-AMP criteria

# 265 3 RESULTS

The MMR-specific ACMG/AMP criteria are listed on https://cspec.genome.network. A total of 19 criteria are specified, with 35 variations of the criteria when including the different strength options. Of these, nine were not used (PS4, PM1, PM4, PP2, PP5, BP1, BP2, BP3, and BP6). The criteria were the same for all four MMR genes, unless indicated otherwise. The allowable combinations of evidence were also updated based on the ClinGen Sequence Variant Interpretation Recommendation for PM2, Version 1.0 (https://clinicalgenome.org/working-groups/sequence-variant-interpretation/) and the findings from Tavtigian et al.

273

## 3.1 Variant Allele Frequency thresholds (PM2, BA1, and BS1)

275 The population allele frequency of a variant represents the frequency or incidence of the variant in a 276 reference population, such as the genome aggregation database (gnomAD) (Karczewski, 2020). The 277 ACMG/AMP criteria are met when the frequency of a population allele is higher than expected for 278 disease-causing variants (BA1 and BS1), or reciprocally, are rare or non-existent in the reference 279 population, which can imply a possible pathogenic role of the variant (PM2). The CardioDB allele 280 frequency calculator allows the calculation of allele frequency thresholds for both Benign Stand Alone 281 (BA1) or Strong (BS1) evidence for a disease of interest, with appropriate input parameters (Whiffin, 282 2017). These thresholds were adapted from a study that calculated allele frequency thresholds at 99% 283 confidence for each MMR gene (Canson, 2022), using published penetrance and prevalence values. For 284 pathogenic PM2 supporting evidence to be met, the threshold is set at 1/50,000 alleles (Grpmax 285 filtering allele frequency of 0.00002 in gnomAD v4.1.0 dataset).

286

### 287 3.2 Variant type and location (PVS1, PS1, and PM5)

We modified the PVS1 flowchart using recommendations from Tayoun et al. (Tayoun, 2018) to reflect the current understanding of pathogenesis from loss of function variants within MMR genes. We created a simplified version of the PVS1 decision tree (Figure 3) and show the logic for assigning the ACMG/AMP criteria to truncating, canonical splice site (intervening sequence (IVS)±1/2 invariant

Plazzer et al., MMR specific ACMG-AMP criteria

nucleotides within an intron), confirmed splice defect, large genomic alteration, and initiation codonvariants.

294

#### 295 3.2.1 Nonsense/frameshift variants

296 PVS1 is assigned if the variant is predicted to encode a protein termination codon located at least 50 bp 297 before the last exon-exon junction, as per the nonsense-mediated mRNA decay (NMD) rule (Lewis, 298 2003), or, if available, before the reference codon of the most distal (3') truncating variant, 299 unambiguously classified as pathogenic in the last exon of the gene of interest (Figure 3). For MMR 300 genes, the truncated/altered region that is critical to protein function is defined as  $\leq$  codon 753 in *MLH1* 301 using the location of known pathogenic variant *MLH1*: c.2252\_2253del; ≤ codon 891 in *MSH2* using the 302 location of known pathogenic variant MSH2: c.2662del;  $\leq$  codon 1341 in MSH6 using the location of 303 known pathogenic variant MSH6: c.3984 3987dup; and  $\leq$  codon 798 in PMS2 using the  $\geq$ 50 nucleotide 304 NMD-rule.

305

#### 306 3.2.2 Splicing aberrations

307 Variants affecting the canonical splice sites (IVS±1/2) were previously considered pathogenic due to 308 their likely impact on splicing. The ACMG/AMP recommendations by Tayoun et al. provide additional 309 nuance and fine-tuning of the strength of PVS1 based on whether the impact is in-frame, out-of-frame, 310 and/or NMD-based. For canonical splice site variants, PVS1 is met if the predicted splicing alteration 311 results in a frameshift mutation and NMD is predicted. If exon skipping or cryptic splice site usage 312 preserves the reading frame, then PVS1 Strong is to be applied. If exon skipping or cryptic splice site 313 usage disrupts the reading frame, and is not predicted to undergo NMD, then PVS1 Moderate is 314 applied, as per the guidelines of Tayoun et al. PP3 cannot be used together with this criterion as the 315 variant type already incorporates Very Strong prediction. For splicing aberrations confirmed using 316 patient mRNA, PVS1 can be assigned where additional requirements are met, including complete defect 317 (no full-length transcript produced from the variant allele) and confirmation in a minigene assay or an 318 additional RNA assay from an independent laboratory, if it is not a predicted splice site variant.

Plazzer et al., MMR specific ACMG-AMP criteria

#### 320 3.2.3 Large genomic rearrangements

321 MMR exon deletions are considered to meet PVS1 due to deletion of functional domains, altered 322 reading frame, and/or truncation leading to NMD. Exon duplications are presumed to be in tandem 323 (Richardson, 2019) and, if predicted to result in a frameshift with NMD, are considered as PVS1\_Strong, 324 as described in Tayoun et al. Whole gene duplications and other duplications affecting the first and last 325 exons are excluded from this criterion.

#### 326 3.2.4 Variants in the initiation codon

Variants in the initiation codon of *MLH1* are deemed to meet PVS1 owing to previously known and well
 established pathogenic variants at this location (Zhang, 2018). For *MSH6* and *PMS2* initiation codons,
 PVS1\_Strong is recommended due to pathogenic variants reported on LOVD (Fokkema, 2021). For
 *MSH2*, alternative ATGs exist inframe in exon 1 (Cyr, 2012), so this criterion is not applicable at any
 evidence weight.

# 332 3.2.5 Substitution at same position as a previously classified pathogenic variant333 (PS1, PM5)

334 PS1 and PM5 criteria seek to assign evidence based on the pathogenic classification of another variant at 335 the same location. PS1 is Strong evidence derived from another pathogenic variant that causes the same 336 presumed amino acid change or splice site impact. For missense variants, it is required that a splicing 337 defect is neither predicted nor the basis of the other variant's classification. The same presumed amino 338 acid change for both variants implies the same impact on protein function. PM5 is similar except the 339 previously classified variant is for a different amino acid at the same position, with an additional caveat 340 that in silico PP3 is met and only at a Supporting level. This is to ensure the variant to be classified is 341 predicted to be damaging while avoiding overuse of *in silico* predictions at this location if PP3 Moderate 342 was met. For variants affecting the same non-canonical splice site nucleotide as a confirmed pathogenic 343 splice-site variant with similar or worse splicing in silico predictions, PS1 is specified.

Plazzer et al., MMR specific ACMG-AMP criteria

## 345 3.3 In silico predictions (PP3, BP4, AND BP7)

Computed predictions based on combined MAPP-MMR and MaxEntScan predictions for all MLH1, MSH2, and MSH6 missense variants are available online at <a href="https://hci-priors.hci.utah.edu/PRIORS/">https://hci-priors.hci.utah.edu/PRIORS/</a> and therefore can be converted to ACMG criteria evidence using the Bayesian framework LR thresholds. For synonymous and intronic variants, the MMR VCEP approves the use of SpliceAI to predict the impact on splicing. Synonymous and deep intronic variants (past +7/-21 nucleotides within an intron) with predicted non-impact on splicing can be classified as LB using BP4 and BP7.

352

## 353 3.4 Clinical data-driven rules

3.4.1 Phenotype and segregation data (PP4, PS2, PM3, PM6, PP1, BP5, BS2, and355 BS4)

356 Phenotype evidence is based on the MSI/MMR IHC pattern in colorectal or endometrial cancer tumors, 357 which are a hallmark of LS. The number of tumors required correspond to the odds calculated in 358 published methods (Thompson, 2013) (Thompson, 2014) and have been recently updated (Li, 2020). 359 Briefly, MSI and somatic BRAF mutation characteristics were used to assign odds ratios to tumor 360 phenotypes, derived as the ratio of characteristics of known pathogenic carrier cases versus that of 361 known non-carrier cases. Finally, the number of tumors required to meet the odds ratios, as defined in 362 the Bayesian framework of the ACMG/AMP criteria, were assigned the corresponding strength of the 363 ACMG/AMP criteria.

364

365 For PP4 evidence, the number of colorectal or endometrial cancer tumors is counted; whereby, one 366 MSI-H tumor is PP4 (Supporting), two is Moderate, and three or more is Strong. Multiple tumors can be 367 included from an individual patient if they are independent tumors. Somatic MLH1 promoter 368 methylation should be excluded in MLH1-/PMS2- tumors. Loss of expression of MMR genes by IHC 369 evidence should be consistent with the variant gene and the protein that is tested and must take into 370 account the MutSa and MutLa heterodimers: MLH1 and PMS2 loss is consistent with an MLH1 371 pathogenic variant, MSH2 and MSH6 loss is consistent with an MSH2 pathogenic variant, MSH6 loss is 372 consistent with an MSH6 pathogenic variant, and PMS2 loss is consistent with a PMS2 pathogenic 373 variant.

Plazzer et al., MMR specific ACMG-AMP criteria

374

375 BP5 requires two colorectal or endometrial cancer tumors with MSS and/or no loss of MMR protein 376 expression, or LS-spectrum tumors with a loss of MMR protein(s) that is inconsistent with the variant 377 gene. BP5 can also be met with one BRAF V600E mutation tumor (colorectal cancer alone) or MLH1 378 methylation (in LS-spectrum tumor alone) with MSI-H/MLH1 loss. For BP5, MSS is an indicator of a 379 benign role for the variant. Originally, only one MSS tumor was required to meet BP5, as per the odds 380 ratio calculations. However, upon classifying several variants as LB with one tumor combined with in 381 silico BP4, the VCEP decided that this could lead to unwarranted LB classification. Thus, while the 382 Bayesian analysis may indicate a benign classification, the experience of clinical experts overruled 383 quantitatively derived evidence in this instance. This is in contrast to the PP4 criteria, which does allow a 384 single tumor to meet the criteria. This may be attributed to the fact that benign criteria are fewer in 385 number and are restricted in strength (Supporting or Strong only); therefore, more stringent criteria are 386 required to meet a benign classification. It may also reflect the possibility that a single incorrect clinical 387 result for tumor characteristics, due to technical issues, phenocopies, or errors, could significantly alter 388 the original Bayesian likelihood analysis. To resolve this issue, it was agreed that two MSS tumors are 389 required to meet BP5 and four are required for BP5 Strong.

390

# 391 3.4.2 Co-segregation odds to assign PP1 (Supporting, Moderate, and Strong) and392 BS4 (Supporting and Strong)

393 Co-segregation odds ratios were used previously for the InSiGHT criteria and are incorporated into the 394 ACMG/AMP criteria. Recently, a web-based tool COsegregation OnLine v3 (COOL v3 Manual), enables 395 a relatively easy way of calculating the co-segregation odds for a given pedigree and, thereby, mapping 396 this to the ACMG/AMP criteria at different strength levels (Belman, 2020). It should also be noted that 397 multiple families with the same variant can have their co-segregation odds multiplied together to 398 produce a more informative result, either in favor or against pathogenicity. For PP1 Strong, there is a 399 requirement for two or more families to be met so that a pathogenic (P/LP) classification is not reached 400 based on data from one family alone.

Plazzer et al., MMR specific ACMG-AMP criteria

#### 402 3.4.3 De novo variants (PS2/PM6)

403 Criteria for de novo variants are based on the 2018 ClinGen Sequence Variant Interpretation 404 Recommendation for de novo Criteria (PS2/PM6) guidelines, Version 1.1 405 (https://clinicalgenome.org/working-groups/sequence-variant-interpretation/), for a points-based scale 406 using tumor characteristics (MSI/IHC) from any LS-spectrum tumors to meet the criteria for pathogenic 407 evidence. This criteria allows multiple cases of de novo variants to be combined using the points-based 408 system (Table 2).

409

#### 410 3.4.4 Co-occurrence with a known P/LP variant (PM3, BS2)

411 For classification of variants seen in LS-suspected cases, evidence towards or against pathogenicity can 412 be assigned (Table 3) if the variants co-occur in trans with known P/LP variants in the same gene. The 413 evidence is in a benign or pathogenic direction, depending on whether cases have constitutional 414 mismatch repair deficiency (CMMRD), which is caused by biallelic pathogenic MMR variants and 415 predisposition to childhood cancer. A variant in cases of CMMRD can be assigned to PM3 if the CMMRD 416 international working group recommendations are met (Table 4), as recommended by the CMMRD 417 international working group (Aronson, 2022). Strong evidence for a benign role (BS2) is recommended if 418 the CMMRD phenotype is not present in patients with an LS-associated cancer, over 45 years of age and 419 with a known pathogenic variant in trans in the same gene. Careful consideration is required of cancer 420 risk for MSH6 and PMS2 variants, as heterozygous variants in these genes may not significantly increase 421 disease risk and the CMMRD phenotype may not be expressed or may be expressed at a later stage. 422

# 423 3.5 Experimental data-driven rules for PS3 (Supporting, Moderate, and 424 Strong) and BS3 (Supporting and Strong)

Functional assay data that follows the functional assay flowchart (Figure 2) to arrive at a deficient or proficient function can meet PS3\_Moderate or BS3\_Moderate. The functional assay flowchart is a general framework for evaluating functional assays that were already performed, or from historic publications, and is not recommended for prospective studies on variants. The VCEP recommends use of the calibrated assays for prospective testing. For calibrated assays, variants can reach a maximum of PS3/BS3 level. Other assays were validated with the recommendations of Brnich et al., as per

Plazzer et al., MMR specific ACMG-AMP criteria

431 Supplementary Table 1. For missense or in-frame indel variants, MMR activity, protein 432 expression/stability, and subcellular location are required to determine if the function is deficient or 433 proficient, when complete splicing impact is not shown.

434

## 435 3.6 Unused criteria (PS4, PM1, PM4, PP2, PP5, BP1, BP2, BP3, and BP6)

- PS4 Due to the availability of tumor IHC data for variant classification (see PP4), PS4 has not been
  utilized for MMR variant classification using proband counting.
- 438 PM1 Located in a mutational hot spot and/or critical and well-established functional domain. There are
- 439 no recognized mutational hot spots that could be used for classification purposes. While there are
- 440 functional domains in the MMR genes, the distribution of pathogenic variants is generalized over all the
- 441 domains (unpublished data).
- 442 PM4 Protein length change from an in-frame variant is not used due to lack of evidence.
- 443 PP2 Missense variant in a gene with low rate of benign missense changes does not apply.
- 444 PP5 Not recommended by ClinGen/SVI WG (Biesecker, 2018).
- 445 BP1 Missense variant in a gene where only loss of function causes disease is not applicable.
- 446 BP2 BS2 is used instead.
- 447 BP3 In-frame deletions/insertions in a repetitive region without a known function is not used.
- 448 BP6 Not recommended by ClinGen/SVI WG (Biesecker, 2018).

## 449 3.7 Validation through pilot variant classification

The set of 48 variants in the pilot batch covered a range of variant types commonly encountered in genetic testing, including 27 presumed missense, 3 presumed synonymous, 3 last base of exon single nucleotide variant, 8 splice site, 4 intronic, 1 in-frame deletion, 1 nonsense, and 1 frameshift (Table 5). Final consensus classifications show that 28 variants (58%) reached a P/LP classification and 12 (25%) reached a B/LB classification; the remaining eight (17%) were VUS.

We compared the final ACMG/AMP-based classifications to the InSiGHT criteria classifications. It should be noted that the InSiGHT criteria included Bayesian methodology, which informed the VCEP on the number of tumors to count for PP4 and BP5 criteria, therefore general concordance was expected. Bayesian probabilities of pathogenicity that were calculated using tumor characteristics, segregation, and CIMRA functional data were compared to the ACMG/AMP classifications by converting the Bayesian

Plazzer et al., MMR specific ACMG-AMP criteria

probability using standard International Agency for Research on Cancer (IARC) probability categories for
assigning B/LB (0.001/0.05) and P/LP (0.99/0.95).

462 The results show concordance of 40/48 (83%) variants between the ACMG/AMP and the InSiGHT criteria 463 classifications. Reasons for discordance include four classifications that were achieved only with 464 ACMG/AMP criteria evidence: PM5/PS1 (other variant at the same location classified as pathogenic). 465 PVS1\_Strong (last base of exon criteria), or BP4 (Missense variant with HCI combined MAPP+PolyPhen-2 466 prior probability). These evidence types were not used by the InSiGHT criteria. For three variants, the 467 VCEP deemed that the InSiGHT classification using Bayesian probability was not appropriate due to 468 insufficient clinical evidence, which also required changing the BP5 criteria to reflect this. Finally, one 469 variant, *MLH1* c.1889T>A, reached 97% probability of pathogenicity based on tumor (PP4 Supporting), 470 segregation data (PP1 Supporting), and in silico data (PP3 Moderate); however, this evidence combined 471 with rare allele frequency (PM2 Supporting), Class 4 was not met using the ACMG/AMP combining 472 rules. Overall, 47/48 (98%) of the ACMG/AMP-based classifications were concordant with InSiGHT 473 outcomes or deemed by the VCEP to be more clinically appropriate.

474

475 Finally, the ACMG/AMP classifications were compared with clinical testing classifications on ClinVar. 476 During which, 20/22 (91%) ClinVar variants were concordant with the ACMG/AMP classifications. An 477 additional 23 variants on ClinVar had conflicting laboratory-submitted interpretations and 17 are now 478 classified as P/LP or B/LB by this VCEP. The 3-star rating given to VCEP classifications will resolve the 479 conflicting interpretations. One variant, MLH1 c.2041G>C, was classified as LP on ClinVar but was a VUS 480 using our ACMG/AMP criteria. The discrepancy was due, in part, to in silico analysis of protein structure 481 showing a deleterious impact, reported by laboratories on ClinVar. However, the calibrated in silico prior 482 probability used by this VCEP does not indicate an impact. Two variants, MSH6 c.1723G>T and MLH1 483 c.1646T>C, were reported on ClinVar as VUS from single submitters without any evidence provided, 484 while the ACMG/AMP classification is LP for both. For these discordant variants, the VCEP 3-star 485 classifications would take precedence over the existing laboratory-submitted classifications of LP.

## 486 4 Discussion

487 The VCEP approach of multidisciplinary experts and adoption of the ACMG/AMP criteria has been 488 successful in achieving consensus and clinical validity for the complex task of variant interpretation 489 (Ritter, 2019). The VCEP membership and classification process shares a strong overlap and similarity

Plazzer et al., MMR specific ACMG-AMP criteria

490 with the previous InSiGHT approach for variant classification. Adopting the ACMG/AMP criteria provides 491 a solid foundation for organizing gene-disease-specific knowledge and experience and adds flexibility to 492 use information that had not been formally calibrated for multifactorial likelihood analysis. In this work, 493 we have implemented the ACMG/AMP-based criteria, superseding previous criteria for MMR genes. Our 494 new ACMG/AMP criteria for LS-specific cancers were used to classify a pilot batch of 48 variants across a 495 range of variant types, with diverse evidence to achieve pathogenic and benign classifications for 83% of 496 variants. It is important to note that, owing to the selection of variants with available evidence for 497 classification, it is not a representative sample of the whole variome for LS.

498 There are several important points to consider while using these criteria. The criteria apply to patients 499 with LS-spectrum tumors, and specifically colorectal or endometrial cancer tumors for certain criteria. 500 Although the CMMRD phenotype is a part of the criteria, variants should only be classified in the context 501 of LS. We highlight that variants can be classified as B/LB for LS while causing the CMMRD phenotype in 502 biallelic cases because of null/low penetrance in heterozygous carriers. Further development of the 503 criteria is likely; therefore newer versions may provide different classifications of variants. Updated 504 guidance and recommendations from ClinGen should also be considered alongside these criteria, as the 505 ACMG/AMP criteria evolve due to advancements in variant classification, such as the recently proposed 506 in silico analyses (Pejaver, 2022).

507 The advantages of the ACMG/AMP framework, as compared to our previous InSiGHT criteria, are 508 evident. It is more flexible in combining disparate types of evidence than the InSiGHT criteria, which 509 used predetermined combinations of evidence alongside a Bayesian multifactorial component. 510 However, despite the ACMG/AMP criteria being compatible with Bayesian reasoning, in certain cases it 511 may not reach a classification that the strictly Bayesian multifactorial likelihood calculation approach 512 would provide. This may be a possible avenue for fine-tuning of the criteria. Nevertheless, the new 513 ACMG/AMP criteria for the MMR genes, with set minimum thresholds for evidence (e.g., BA1, BS1 allele 514 frequency thresholds, in silico odds, tumor characteristics, functional assay odds, and co-segregation 515 odds), varied evidence types, and logical combining rules, will fill a valuable role in the classification 516 process for clinical genetics. A purely quantitative approach might have less usability in routine clinical 517 diagnostics due to inherent complexity or impracticality. This is evident in the global uptake of the 518 ACMG/AMP criteria and the sharing of classification criteria between different VCEPs for improving the 519 criteria over time. Overall, these new criteria complement the MMR-specific Bayesian multifactorial 520 likelihood methods and supersede the previous InSiGHT classification criteria for MMR genes, providing

Plazzer et al., MMR specific ACMG-AMP criteria

521 capacity for wider clinical application. This VCEP supports expert specifications to the original 522 ACMG/AMP criteria, owing to elaborate gene-specific criteria for frequently analyzed genes, such as 523 MMR, to improve clinical care.

# 524 5 Conclusion

525 The ACMG/AMP criteria offer a flexible and standardized system for MMR variant classification, with 526 gene-disease-specific knowledge to enhance the criteria. By adopting existing recommendations and 527 incorporating efforts from functional assays, computational analyses, and clinical domains, a coherent 528 and practical set of criteria for variant classification was achieved for MMR genes, using the ACMG/AMP 529 framework. These MMR-specific ACMG/AMP criteria set a foundation, with the ability to include 530 additional in silico predictors, functional assays, and clinical evidence, as science advances over time. 531 The InSiGHT ClinGen VCEP will employ these criteria for ongoing MMR variant classifications and will 532 seek to update and enhance the criteria in alignment with ClinGen and other VCEP groups.

533

# 534 6 Data availability

- 535 Variant classifications are published in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) and
- 536 curated evidence is available on the ClinGen Evidence Repository
- 537 (https://erepo.clinicalgenome.org/evrepo/).

538

# 539 7 Acknowledgments

540 JPP was supported by the Alan Watt and Chris Geyer Oncology Fellowship through The Royal Melbourne 541 Hospital Foundation and NIH PA-18-591 Administrative Supplements to Promote Data Sharing in Cancer 542 Epidemiology Studies. ABS was supported by NHMRC Funding (APP1104808). Grant funding for MKC: 543 Cancer Council NSW, RG19-1. In Spain, this study has been partially funded by Ministerio de Ciencia e 544 Innovación, which is part of Agencia Estatal de Investigación (AEI), through the Retos Investigación 545 grant, number PID2019-111254RB-I00, and La Marató de TV3 (202028-30). We also thank CERCA 546 Programme / Generalitat de Catalunya for institutional support. MG was supported by Italian Ministry of 547 Health RC 2022. KA and GY was supported by Japan Agency Medical Research and Development (AMED) 548 under grant JP 18kk0205004, JSPS KAKENHI Grant Number JP18K07339 and JP22K07266. We would like 549 to thank Ms. Lubaina Koti for editing the manuscript for language, structure, and accuracy. We 550 acknowledge Marissa Rose for analysis of an early draft of the criteria.

Plazzer et al., MMR specific ACMG-AMP criteria

551

552

# 553 8 Conflict of Interests

- 554 Becky Milewski previously had a role with the pilot variant classification efforts in 2020/2021. She was
- 555 previously an employee of GeneDx, LLC.
- 556 Lauren Currie is an employee of GeneDx, LLC
- 557 Ester Borras is an employee and shareholder of Invitae Corporation.
- 558 John Paul Plazzer has previously consulted as curator for an external diagnostic testing company.

559

		BENIGN	CRITERIA	PATHOGENIC CRITERIA			
Strength of evidence		Strong	Supporting	Supporting	Moderate	Strong	Very Strong
Odds of Pathogenicity		-18.7	-2.08	2.08	4.33	18.7	350.0
ş	Population Data	BA1 BS1 BS2		PM2		<del> PS4</del>	
- DG	Allelic Evidence &	BS4		PP1			
Category and ACMG/AMP Codes	Cosegregation Data	←	BP2 BP5		PM3 PM6	PS2	
			-BP1-	-PP2-	PM1 ←	PS1	
Corresponding	Computation & Predictive Data		BP3 BP4 BP7	PP3 —	PM5		PVS1
orres	Functional Data	BS3-		←		PS3	
°	Other		-BP6-	PP4	1	<u> </u>	

560

Figure 1. Specifications of the ACMG/AMP criteria. Arrows indicate the range of strength of the evidence,
adapted from (Strande, 2018). BA1 is included with Strong criteria even though it is Stand Alone
strength. PM3, PM6, and PS2 are subject to strength changes using a points-based system.

564

565

Plazzer et al., MMR specific ACMG-AMP criteria





Figure 2. Flowchart demonstrating the interpretation of functional assay data, adapted from Thompson
et al. 2020. If RNA splicing is used for PVS1, it should not be used for PS3.

Plazzer et al., MMR specific ACMG-AMP criteria



570

571 Figure 3. The PVS1 decision tree, adapted from Tayoun et al. 2018.

Plazzer et al., MMR specific ACMG-AMP criteria

- 574 RULES FOR COMBINING PATHOGENIC CRITERIA Adjusted for Bayesian consistency
- 575 Pathogenic
- 576 1.1 Very Strong AND
- 577 a. ≥1 Strong OR
- 578 b. ≥1 Moderate OR
- 579 c. ≥2 Supporting
- 580 2. ≥2 Very Strong
- 581 3. ≥3 Strong
- 582 4.1 Strong AND
- 583 a. ≥3 Moderate OR
- b. 2 Moderate AND ≥2 Supporting OR
- 585 c. 1 Moderate AND ≥4 Supporting
- 586 Likely Pathogenic
- 587 1. 1 Very Strong AND 1 Supporting
- 588 2. 2 Strong
- 589 3.1 Strong AND 1--2 Moderate
- 590 4.1 Strong AND  $\geq$ 2 Supporting
- 591 5. ≥3 Moderate
- 592 6.2 Moderate AND ≥2 Supporting
- 593 7.1 Moderate AND ≥4 Supporting
- 594
- 595 RULES FOR COMBINING BENIGN CRITERIA
- 596 Benign
- 597 1.1 Stand--Alone (BA1)
- 598 2. ≥2 Strong (BS1--BS4)
- 599 Likely Benign
- 600 1.1 Strong and 1 Supporting
- 601 2. ≥2 Supporting
- 602 SVI WG Recommendation for De Novo Criteria (PS2 & PM6) Version 1.0
- https://clinicalgenome.org/site/assets/files/3461/svi\_proposal\_for\_de\_novo\_criteria\_v1\_0.pdf
  https://clinicalgenome.org/site/assets/files/3461/svi\_proposal\_for\_de\_novo\_criteria\_v1\_0.pdf
  for de\_novo\_criteria\_v1\_0.pdf
  for de\_novo\_criteria\_v1\_0.pdf
- 609 strength level.

Plazzer et al., MMR specific ACMG-AMP criteria

<b>Supporting</b> (PM6_Supporting)	Moderate (PS2_Moderate or PM6)	<b>Strong</b> (PS2 or PM6_Strong)	Very Strong (PS2_VeryStrong or PM6_VeryStrong)	
0.5	1	2	4	

- 611 ClinGen Sequence Variant Interpretation Recommendation for in trans Criterion (PM3) Version 1.0
- 612 <u>https://www.clinicalgenome.org/site/assets/files/3717/svi\_proposal\_for\_pm3\_criterion\_-</u>
- 613 version 1.pdf
- 614
- 615 Table 3. Recommendation for determining the appropriate ACMG/AMP evidence strength level for *in*
- 616 *trans* occurrence(s)

	<b>Supporting</b> (PM3_Supporting)	Moderate (PM3)	<b>Strong</b> (PM3_Strong)	<b>Very Strong</b> (PM3_VeryStrong)
	0.5	1	2	4
617				
618				
619 620				
620 621				
622				
623				
624				
625				
626 627				
628				
629				
630				
631				
632				
633				

Plazzer et al., MMR specific ACMG-AMP criteria

634	Table 4: Scoring system for aiding CMMRD diagnosis from C4CMMRD (adapted from Aronson et al
635	2022; PMID: 33622763)

Malignancies/premalignancies: one is mandatory; if more than one is present in the patient, add the points:	>=3 points = CMMRD features meets PM3 criteria after excluding the diagnosis of NF1 or LFS as individuals with those disorders could easily get to 3 points.
Carcinoma from the LS spectrum* at age <25 years.	3 points
Multiple bowel adenomas at age <25 years and absence of APC/MUTYH mutation(s) or a single high-grade dysplasia adenoma at age <25 years.	3 points
WHO grade III or IV glioma at age <25 years.	2 points
NHL of T cell lineage or sPNET at age <18 years	2 points
Any malignancy at age <18 years.	1 point
Additional features: optional; if more than one of the following is present, add the points:	
Clinical sign of NF1 and/or $\geq$ 2 hyperpigmented and/or hypopigmented skin alterations Ø>1 cm.	2 points
Diagnosis of LS in a first-degree or second-degree relative.	2 points
Carcinoma from LS spectrum* before the age of 60 in a firstdegree, second- degree or third-degree relative.	1 point
A sibling with carcinoma from the LS spectrum*, high-grade glioma, sPNET or NHL.	2 points
A sibling with any type of childhood malignancy.	1 point
Multiple pilomatricomas in the patient.	2 points
One pilomatricoma in the patient.	1 point
Agenesis of the corpus callosum or non-therapy-induced cavernoma in the patient.	1 point
Consanguineous parents	1 point
Deficiency/reduced levels of IgG2/4 and/or IgA.	1 point

\*Colorectal, endometrial, small bowel, ureter, renal pelvis, biliary tract, stomach, bladder carcinoma

CMMRD, constitutional mismatch repair deficiency; LS, Lynch syndrome; NF1, neurofibromatosis type 1; NHL, non-Hodgkin's lymphoma; sPNET, supratentorial primitive neuroectodermal tumours.

636 637

638

000

Plazzer et al., MMR specific ACMG-AMP criteria

#### 640 Table 5: Comparison of ACMG/AMP and InSiGHT criteria classifications.

	Predicted protein		ACMG/AMP	ACMG/AMP	InSiGHT	Concord/Disco
Variant	change	Variant type	criteria met	Class	Class	rd
			BS1, BP4, BP7,			
MLH1:c.42A>C	p.(Thr14=)	Synonymous	BS4	Benign	Benign	Concordant
MLH1:c.1732-						
19T>A		Intronic	BA1, BS3	Benign	Likely Benign	Concordant
MSH6:c.107C>T	p.(Ala36Val)	Missense	BS1, BP4, BS2	Benign	Likely Benign	Concordant
MLH1:c.649C>T	p.(Arg217Cys)	Missense	BS3, BS1, BP5	Benign	Likely Benign	Concordant
			PM2_supportin			
MLH1:c.2074T>C	p.(Ser692Pro)	Missense	g, BP4, BS4	Likely benign	Benign	Concordant
MSH2:c.1277-						
16T>C		Intronic	BP4, BS1	Likely benign	Likely Benign	Concordant
MSH2:c.1748A>G	p.(Asn583Ser)	Missense	BP4, BS3	Likely Benign	Likely Benign	Concordant
			BP5,			
			BS4_supportin			
			g,			
			BS3_supportin			
			g, PP3 moderate,			
MSH2:c.913G>A	p.(Ala305Thr)	Missense	BS2	Likely benign	Likely Benign	Concordant
WI3112.0.91302A	p.(Ala505111)	IVIISSEIISE	52	LIKEly Dellight	Likely benign	Concordant
MSH2:c.1563T>C	p.(Tyr521=)	Synonymous	BS1, BP4, BP7	Likely benign	Likely Benign	Concordant
10112.0.1303170	p.(191321-7	Synonymous	PM2_supportin	Likely beingh	Entery Demgi	concordant
MLH1:c.2040C>T	p.(Cys680=)	Synonymous	g, BP4, BP7	Likely Benign	Likely Benign	Concordant
WEITE: 0.2040021	p.(cy3000-)	Synonymous	PM2_supportin	Likely beingh	Entery Demgi	concordant
			g, BP4,			
			BS3_supportin			
MLH1:c.277A>G	p.(Ser93Gly)	Missense	g	Likely benign	Likely Benign	Concordant
MSH6:c.3482CTG[		Inframe	PM2_supportin	Likely	Likely	
1]	p.(Ala1162del)	deletion	g, PS3, PP4	pathogenic	pathogenic	Concordant
MLH1:c.1558+1G			PM2_supportin	Likely	Likely	
>A		Splice site	g, PVS1	Pathogenic	Pathogenic	Concordant
MSH2:c.2210+2T			PM2_supportin	Likely	Likely	
>C		Splice site	g, PVS1	pathogenic	pathogenic	Concordant
			PM2_supportin			
			g,			
MSH2:c.792+1G>		Calling in	PVS1_strong,	Likely	Likely	Constant
Т		Splice site	PP4	pathogenic	Pathogenic	Concordant
			PP1_strong, PP3_moderate,			
			PM2 supportin	Likely	Likely	
MLH1:c.1646T>C	p.(Leu549Pro)	Missense	g	pathogenic	pathogenic	Concordant
	1-1-000 101107		PP4,	patrice Berlie	participation	concorrante
PMS2:c.1144+1G			PM2 supportin	Likely	Likely	
>A		Splice site	g, PVS1_strong	pathogenic	pathogenic	Concordant
			PS3, PP3,			
			PM2_supportin	Likely	Likely	
MSH6:c.1296T>G	p.(Phe432Leu)	Missense	g	pathogenic	Pathogenic	Concordant

Plazzer et al., MMR specific ACMG-AMP criteria

		•				
			PVS1_strong,			
			PP4_moderate,			
			PM2_supportin	Likely	Likely	
PMS2:c.989-2A>G		Splice site	g	pathogenic	pathogenic	Concordant
			PM2_supportin			
			g, PP3, PP1,			
			PP4_strong,	Likely		
MSH2:c.1807G>A	p.(Asp603Asn)	Missense	PS3_moderate	pathogenic	Pathogenic	Concordant
			PM2_supportin			
			g, PP3, PP4,	Likely		
MSH6:c.1282A>G	p.(Lys428Glu)	Missense	PS3	pathogenic	Pathogenic	Concordant
			PM2_supportin			
	(1. 69.4)		g, PP4_strong,	Likely		
MSH2:c.1862G>T	p.(Arg621Leu)	Missense	PP3_moderate	pathogenic	Pathogenic	Concordant
			PM2_supportin			
	(, )		g, PP4_strong,	Likely		
MSH6:c.1723G>T	p.(Asp575Tyr)	Missense	PP3_moderate	pathogenic	Pathogenic	Concordant
			PM5,			
			PM2_supportin			
			g,			
			PP1_moderate,			
			PP3_moderate,	Likely		
MLH1:c.350C>G	p.(Thr117Arg)	Missense	PP4_moderate	pathogenic	Pathogenic	Concordant
			PM5,			
			PM2_supportin			
			g,			
MCU2 400CLT			PP3_moderate,	Likely	Dethermite	Concentent
MSH2:c.490G>T	p.(Gly164Trp)	Missense	PP4_moderate	pathogenic	Pathogenic	Concordant
			PVS1,	Libraho		
	(n (Clu91Tor)	Nonconco	PM2_supportin	Likely	Dathagania	Concordont
PMS2:c.241G>T	(p.(Glu81Ter)	Nonsense	g	pathogenic	Pathogenic	Concordant
MLH1:c.790+1G>			PM2_supportin		Likely	
Т		Splice site	g, PVS1, PP3	Pathogenic	Pathogenic	Concordant
MSH2:c.366+1G>			PM2_supportin		Likely	
С		Splice site	g, PVS1, PP1	Pathogenic	Pathogenic	Concordant
			PM5,			
			PM2_supportin			
			g,			
			PP3_moderate,			
			PP4_moderate,		Likely	
MSH2:c.929T>G	p.(Leu310Arg)	Missense	PP1_strong	Pathogenic	Pathogenic	Concordant
			PVS1,			
			PM2_supportin		Likely	
MLH1:c.589-2A>C		Splice site	g, PP4	Pathogenic	Pathogenic	Concordant
		Last base of	PM2_supportin			
MSH2:c.1276G>A	p.(Gly426Arg)	exon	g, PP4, PVS1	Pathogenic	Pathogenic	Concordant
			PM2_supportin			
			g, PS3,			
			PP3_moderate,			
MSH2:c.2075G>T	p.(Gly692Val)	Missense	PP4_strong	Pathogenic	Pathogenic	Concordant
			PM2_supportin			
			g, PVS1,			
	(p.(Gly525ArgfsTer		PM3_supportin			
PMS2:c.1571dup	17)	Frameshift	g	Pathogenic	Pathogenic	Concordant

Plazzer et al., MMR specific ACMG-AMP criteria

		1				
			PS3,			
			PM2_supportin			
			g, PP1,			
			PP3_moderate,			
MSH2:c.1012G>A	p.(Gly338Arg)	Missense	PP4 moderate	Pathogenic	Pathogenic	Concordant
			PS3,			
			PP1_strong,			
			PM2_supportin			
			g,			
MLH1:c.923A>C	p.(His308Pro)	Missense	PP3_moderate	Pathogenic	Pathogenic	Concordant
			PVS1,			
MSH2:c.2459-			PM2_supportin			
12A>G		Intronic	g, PP4_strong	Pathogenic	Pathogenic	Concordant
			PM2_supportin	Uncertain	Uncertain	
		Missource				Concerdant
PMS2:c.1753C>A	(p.(Leu585Ile)	Missense	g, BP4	significance	significance	Concordant
			PM2_supportin			
			g, PM3, PP4,	Uncertain	Uncertain	
PMS2:c.614A>C	(p.(Gln205Pro)	Missense	PP3	significance	significance	Concordant
			PM2_supportin	Uncertain	Uncertain	
MLH1:c.2041G>C	p.(Ala681Pro)	Missense		significance		Concordant
WILTI.C.20410/C	p.(Ald001P10)	IVIISSEIISE	g, PP4	Significance	significance	Concordant
			PP4_strong,			
			PM2_supportin	Uncertain	Uncertain	
MLH1:c.2042C>T	p.(Ala681Val)	Missense	g	significance	significance	Concordant
					Uncertain	
MSH6:c.663A>C	p.(Glu221Asp)	Missense	BS1, BP4	Likely benign	significance	Discordant
	p.(0102221.00)	whosense	PM2_supportin	Linery beingh	Significance	Discordant
			g,			
MSH2:c.2634+5G			PP4_moderate,	Likely	Uncertain	
>T		Intronic	PS1, PP3	pathogenic	significance	Discordant
			PVS1_strong,			
			PP4_moderate,			
		Last base of	PM2 supportin	Likely	Uncertain	
MLH1:c.1667G>A	p.(Ser556Asn)	exon	g	pathogenic	significance	Discordant
	p.(00.000/01/)		PVS1,	Patrio Berno		
		Last base of	,		Uncertain	
		Last base of	PM2_supportin	Dethersis		Discondent
MSH2:c.211G>C	p.(Gly71Arg)	exon	g, PP4_strong	Pathogenic	significance	Discordant
			BS4_supportin	Uncertain		
MSH6:c.884A>G	p.(Lys295Arg)	Missense	g	significance	Likely Benign	Discordant
			PM2_supportin	Uncertain		
	p.(Ala424Thr)	Missense	- · ·		Likoly Popian	Discordant
MLH1:c.1270G>A	p.(Ald4241111)	wiissense	g, BP4	significance	Likely Benign	Discordant
			PM2_supportin	Uncertain		
MLH1:c.1963A>T	p.(Ile655Phe)	Missense	g, BP4	significance	Likely Benign	Discordant
			PM2_supportin			
			g, PP1,			
			PP3_moderate,	Uncertain	Likely	
MLH1:c.1889T>A	p.(Ile630Asn)	Missense	PP4	significance	Pathogenic	Discordant
WILLITTO 2124	p.(iieusuAsii)	11112261126	174	Significance	ratilogenic	DISCUINDIIL

642

643

644

Plazzer et al., MMR specific ACMG-AMP criteria

# 646 References

- 647 André, T., 2020. Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer.
- 648 New England Journal of Medicine, pp. 2207-2218.
- 649 Aronson, M., 2022. Diagnostic criteria for constitutional mismatch repair deficiency (CMMRD):
- recommendations from the international consensus working group. *Medical Genetics*, pp. 318-327.
- Belman, S., 2020. Considerations in assessing germline variant pathogenicity using
- 653 cosegregation analysis. *Genetics in Medicine*, 22(12), pp. 2052-2059.
- 654 Biesecker, L. a. H. S., 2018. The ACMG/AMP reputable source criteria for the interpretation of 655 sequence variants. *Genetics in Medicine*, 20(12), pp. 1687-1688.
- Biller, L., 2022. Lynch Syndrome-Associated Cancers Beyond Colorectal Cancer.
- 657 Gastrointestinal Endoscopy Clinics of North America, pp. 75-93.
- Brnich, S., 2020. Recommendations for application of the functional evidence PS3/BS3 criterion
- using the ACMG/AMP sequence variant interpretation framework. *Genome medicine*, 12(1), pp.1-12.
- 661 Canson, D., 2022. The splicing effect of variants at branchpoint elements in cancer genes. 662 *Genetics in Medicine*, 24(2), pp. 398-409.
- 663 Cyr, J., 2012. The predicted truncation from a cancer-associated variant of the MSH2 initiation 664 codon alters activity of the MSH2-MSH6 mismatch repair complex. *Molecular carcinogenesis,*
- 665 51(8), pp. 647-658.
- 666 Dominguez-Valentin, M., 2020. Cancer risks by gene, age, and gender in 6350 carriers of
- 667 pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database.
- 668 *Genetics in Medicine,* 22(1), pp. 15-25.
- 669 Dominguez-Valentin, M., 2021. No difference in penetrance between truncating and
- 670 missense/aberrant splicing pathogenic variants in MLH1 and MSH2: a prospective lynch
- 671 syndrome database study. *Journal of clinical medicine*, 10(13), p. 2856.
- 672 Dominguez-Valentin, M., 2023. Mortality by age, gene and gender in carriers of pathogenic
- 673 mismatch repair gene variants receiving surveillance for early cancer diagnosis and treatment: a 674 report from the prospective Lynch syndrome database. *EClinicalMedicine.*
- 675 Drost, M., 2019. A functional assay–based procedure to classify mismatch repair gene variants
- 676 in Lynch syndrome. *Genetics in Medicine*, 21(7), pp. 1486-1496.
- 677 Drost, M., 2020. Two integrated and highly predictive functional analysis-based procedures for
- 678 the classification of MSH6 variants in Lynch syndrome. *Genetics in Medicine*, 22(5), pp. 847-679 856.
- 680 Fokkema, I., 2021. The LOVD3 platform: efficient genome-wide sharing of genetic variants.
- European Journal of Human Genetics, 29(12), pp. 1796-1803.
- 682 Georgeson, P., 2019. Tumor mutational signatures in sebaceous skin lesions from individuals 683 with Lynch syndrome. *Molecular Genetics & Genomic Medicine*, p. e00781.
- Jia, X., 2021. Massively parallel functional testing of MSH2 missense variants conferring Lynch
- 685 syndrome risk. *The American Journal of Human Genetics*, 108(1), pp. 163-175.
- 686 Kahn, R., 2019. Universal endometrial cancer tumor typing: How much has
- 687 immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis
- of Lynch syndrome across the population?. *Cancer*, 125(18), pp. 3172-3183.

Plazzer et al., MMR specific ACMG-AMP criteria

- 689 Karczewski, K. J. F. L. C. T. G. C. B. B. A. J. W. Q. .. & M. D. G., 2020. The mutational
- constraint spectrum quantified from variation in 141,456 humans.. *Nature*, 581(7809), pp. 434-443.
- Latham, A., 2019. Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer. *Journal of clinical oncology*, 37(4), p. 286.
- Lewis, B., 2003. Evidence for the widespread coupling of alternative splicing and nonsense-
- 695 mediated mRNA decay in humans. *Proceedings of the National Academy of Sciences*, 100(1), 696 pp. 189-192.
- Li, S., 2020. Tumour characteristics provide evidence for germline mismatch repair missense
   variant pathogenicity. *Journal of Medical Genetics*, 57(1), pp. 62-69.
- Nugroho, P., 2022. Risk of cancer in individuals with Lynch-like syndrome and their families: a
- systematic review. Journal of Cancer Research and Clinical Oncology, pp. 1-22.
- 701 Pejaver, V., 2022. Calibration of computational tools for missense variant pathogenicity
- 702 classification and ClinGen recommendations for PP3/BP4 criteria. The American Journal of
- 703 Human Genetics.
- Plazzer, J., 2013. The InSiGHT database: utilizing 100 years of insights into Lynch syndrome.
   *Familial cancer*, pp. 175-180.
- 706 Preston, C., 2022. ClinGen Variant Curation Interface: a variant classification platform for the
- application of evidence criteria from ACMG/AMP guidelines. *Genome Medicine*, 14(1), pp. 1-12.
- Rath A, R. A. R. K. G. R. H. J. C. M. T. S. G. J. H. C., 2022. A calibrated cell-based functional
- assay to aide classification of MLH1 DNA mismatch repair gene variants. *Human Mutation*,
  43(12), pp. 2295-2307.
- 711 Rayner, E., 2022. Predictive functional assay-based classification of PMS2 variants in Lynch
- 712 syndrome. *Human Mutation*, 43(9), pp. 1249-1258.
- 713 Reese, M. G. E. F. H. K. D. & H. D., 1997. Improved splice site detection in Genie. *Proceedings*
- of the first annual international conference on Computational molecular biology, pp. 232-240.
- 715 Rehm, H., 2015. ClinGen—the clinical genome resource. *New England Journal of Medicine,*
- 716 372(23), pp. 2235-2242.
- 717 Richardson, M., 2019. DNA breakpoint assay reveals a majority of gross duplications occur in
- tandem reducing VUS classifications in breast cancer predisposition genes. *Genetics in*
- 719 *Medicine,* 21(3), pp. 683-693.
- Richards, S., 2015. Standards and guidelines for the interpretation of sequence variants: a joint
- 721 consensus recommendation of the American College of Medical Genetics and Genomics and
- the Association for Molecular Pathology. *Genetics in medicine,* pp. 405-423.
- Riepe, T., 2021. Benchmarking deep learning splice prediction tools using functional splice
- 724 assays. *Human Mutation*, 42(7), pp. 799-810.
- Ritter, D., 2019. A case for expert curation: an overview of cancer curation in the clinical
- genome resource (ClinGen). *Molecular Case Studies*, 5(5), p. a004739.
- 727 Rivera-Muñoz, E., 2018. ClinGen Variant Curation Expert Panel experiences and standardized
- processes for disease and gene-level specification of the ACMG/AMP guidelines for sequence
   variant interpretation. *Human Mutation*, pp. 1614-1622.
- 730 Scott, A., 2022. Saturation-scale functional evidence supports clinical variant interpretation in
- T31 Lynch syndrome. *Genome Biology*, 23(1), pp. 1-16.


Plazzer et al., MMR specific ACMG-AMP criteria

- 732 Strande, N., 2018. Navigating the nuances of clinical sequence variant interpretation in
- 733 Mendelian disease.. Genetics in Medicine, 20(9), pp. 918-926.
- 734 Tavtigian, S., 2018. Modeling the ACMG/AMP variant classification guidelines as a Bayesian
- 735 classification framework. *Genetics in Medicine*, 20(9), pp. 1054-1060.
- 736 Tayoun, A., 2018. Recommendations for interpreting the loss of function PVS1 ACMG/AMP
- 737 variant criterion. Human mutation, 39(11), pp. 1517-1524.
- 738 Thompson, B., 2013. A multifactorial likelihood model for MMR gene variant classification
- 739 incorporating probabilities based on sequence bioinformatics and tumor characteristics: a report
- 740 from the Colon Cancer Family Registry. Human Mutation, 34(1), pp. 200-209.
- 741 Thompson, B., 2014. Application of a 5-tiered scheme for standardized classification of 2,360
- 742 unique mismatch repair gene variants in the InSiGHT locus-specific database. Nature genetics. 743 pp. 107-115.
- 744 Thompson, B., 2020. Contribution of mRNA splicing to mismatch repair gene sequence variant
- 745 interpretation. Frontiers in genetics. Volume 11. p. 798.
- 746 Tian, Y., 2019. REVEL and BayesDel outperform other in silico meta-predictors for clinical 747 variant classification. Scientific reports, 9(1), pp. 1-6.
- 748 Tiwari, A., 2016. Lynch syndrome in the 21st century: clinical perspectives. QJM: An
- 749 International Journal of Medicine, pp. 151-158.
- 750 Whiffin, N., 2017. Using high-resolution variant frequencies to empower clinical genome
- 751 interpretation. Genetics in Medicine, 19(10), pp. 1151-1158.
- 752 Yeo, G. &. B. C. B., 2004. Maximum entropy modeling of short sequence motifs with
- 753 applications to RNA splicing signals. J Comput Biol, 11(2-3), pp. 377-94.
- 754 Zhang, Y., 2018. A Novel MLH1 Initiation Codon Mutation (c.3G>T) in a Large Chinese Lynch 755 Syndrome Family with Different Onset Age and mRNA Expression Level. BioMed Research International.
- 756
- 757
- 758
- 759
- 760
- 761

762 Supplementary Table 1. Validation of functional assays (See supplementary excel file).

- 763
- 764
- 765
- 766

Plazzer et al., MMR specific ACMG-AMP criteria



- 771
- 772
- 773
- 774

#### 775 APPENDIX

15).

776

#### 777 Important Notes

- 778 *PMS2* NGS results need confirmation by other orthogonal assays as well as functional assessment (e.g.
- T79 Long-Range or cDNA), if variants are located in the PMS2CL pseudogene homologous regions (exons 11-
- 780
- 781
- 782 Gene-specific penetrance estimates are available at <u>http://lscarisk.org/</u>
- 783

#### 784 Justification for last exon PVS1 boundaries:

- 785 Nonsense/frameshift variant introducing Premature Termination Codon (PTC):
- 786 1)  $\leq$  codon 753 in MLH1 using location of known pathogenic variant *MLH1* c.2252\_2253del
- 787 2)  $\leq$  codon 891 in MSH2 using location of known pathogenic variant *MSH2* c.2662del

Plazzer et al., MMR specific ACMG-AMP criteria

- 788 3) ≤ codon 1341 in MSH6 using location of known pathogenic variant *MSH6* c.3984\_3987dup
- 789 4)  $\leq$  codon 798 in PMS2 using  $\geq$ 50 nucleotide NMD-rule.
- 791 Protein Expression and consistency with variant location
- 792 IHC evidence should be consistent with the variant gene and the protein that is tested and take into
- 793 account the MutSα and MutLα heterodimers: MLH1 and PMS2 loss is consistent with an MLH1
- pathogenic variant, MSH2 and MSH6 loss is consistent with an MSH2 pathogenic variant, MSH6 loss is
- consistent with an *MSH6* pathogenic variant, and PMS2 loss is consistent with a *PMS2* pathogenic
- 796 variant.